Trial Profile
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Elan Pharmaceuticals
- 05 Feb 2009 New trial record